Cefea sp. z o.o.sp. k.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2017-09-22
Activity description

Cefea sp. z o.o. provides services to the pharmaceutical sector, including repackaging medicines and packaging and labelling medicinal products and medical devices. It supports clinical trials, imports medicinal products and offers temperature-controlled storage.

Registered address
ul. Działkowa 56, 02-234 Warszawa, Poland
Website
cefea.plWebsite active
Email
Email warning
Phone
Electronic delivery address
AE:PL-88124-71440-CBFUJ-19

Financials

The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2024.

Results vs industry

Revenue
This companyUSD 9.90mMedianUSD 782.27kAverageUSD 24.03m
Net profit
This companyUSD 728.27kMedianUSD 7.91kAverageUSD 2.59m
Operating costs
This companyUSD 9.05mMedianUSD 723.93kAverageUSD 19.92m
Assets
This companyUSD 3.82mMedianUSD 800.34kAverageUSD 29.11m

Industry

Bank accounts

Registered as a VAT taxpayer on 2017-10-16. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

19 public aid cases recorded, with a total value of $299,605.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$3,100
De minimis aid (in accordance with Commission Regulation 2023/2831)
$26,077
De minimis aid (in accordance with Commission Regulation 2023/2831)
$20,516

European Funds

ProjectEU co-financing
CEFEA Sp. z o.o. Sp.K - dotacja na kapitał obrotowy (COVID-19)
$63,196

Tenders

24 tenders recorded as contractor: 9 national ($465,509) and 15 EU ($4,452,595).

SubjectAmount
Dostawa badanych produktów leczniczych (BPL) do fazy b i c badania optimal – HT z usługą transportu i utylizacji
–
ZP/CZD/052/26 Dostawa produktów leczniczych oraz świadczenie usługi przepakowania i etykietowania produktów leczniczych zawierających ewerolimus wraz z ich zwolnieniem do użycia w niekomercyjnym badaniu klinicznym medway „Badanie fazy i dotyczące stosowania inhibitora CDK8 RVU120 w połączeniu z ewerolimusem u dzieci z nawracającym lub postępującym medulloblastoma grupy 3 lub 4"
$332.6K
115.2025 Dostawa leków Ferinject i Tardyferon lub równoważnych oraz soli fizjologicznej (0,9% NaCl) do infuzji na potrzeby badania klinicznego
$9,813

Partners

PartnersPartner role
Daniel Gralak (50)Marital property community
Limited partner
Marcin Paweł Nielepkowicz (51)
General partner
Cefea sp. z o.o.
Cefea sp. z o.o.
General partner

Manner of representation

The general partner, namely CEFEA limited liability company, has the right to independently represent the company. Each member of the management board is authorized to act on behalf of the general partner, namely CEFEA limited liability company, independently. The management board of the general partner consists of: Marcin Nielepkowicz (PESEL No. 75050905438) – member of the management board; Daniel Gralak (PESEL No. 76110705379) – member of the management board.

Beneficial owners

Person

Competitors

Name
ICN Polfa RzeszówS.A.
Curtis Health CapsS.A.
Przedsiębiorstwo Produkcyjno-Handlowe EwaS.A.
Biofaktorsp. z o.o.
Labofarmsp. z o.o.
Labor Przedsiębiorstwo Farmaceutyczno - Chemicznesp. z o.o.

Change history

DateEvent
2018-02-26Address change
2017-09-22Entered in the register

FAQ

Last updated: 2026-04-09